Case Study Description of Solnyx Pharmaceuticals: The Atoxeril Clinical Trial
The head of clinical trials at Solnyx Pharmaceuticals had just been handed the results of a phase II trial of Atoxeril, a hypertension drug. Her task was to interpret these data in preparation for a meeting with her institutional review board and representatives of the Food and Drug Administration. This case introduces a number of concepts related to the analysis of clinical trials including dealing with missing data, ANOVA, regression and sample size calculations. Students will evaluate the design of the phase II clinical trial and interpret the trial results; they will also evaluate the implications of the angioedema incidence and how it might affect the design of a phase III trial.
Swot Analysis of "Solnyx Pharmaceuticals: The Atoxeril Clinical Trial" written by Gregory S. Zaric, James E. Hatch includes – strengths weakness that are internal strategic factors of the organization, and opportunities and threats that Trial Clinical facing as an external strategic factors. Some of the topics covered in Solnyx Pharmaceuticals: The Atoxeril Clinical Trial case study are - Strategic Management Strategies, Financial analysis and Technology & Operations.
Some of the macro environment factors that can be used to understand the Solnyx Pharmaceuticals: The Atoxeril Clinical Trial casestudy better are - – central banks are concerned over increasing inflation, increasing transportation and logistics costs, banking and financial system is disrupted by Bitcoin and other crypto currencies, there is increasing trade war between United States & China, customer relationship management is fast transforming because of increasing concerns over data privacy, technology disruption, increasing energy prices,
wage bills are increasing, cloud computing is disrupting traditional business models, etc
Introduction to SWOT Analysis of Solnyx Pharmaceuticals: The Atoxeril Clinical Trial
SWOT stands for an organization’s Strengths, Weaknesses, Opportunities and Threats . At Oak Spring University , we believe that protagonist in Solnyx Pharmaceuticals: The Atoxeril Clinical Trial case study can use SWOT analysis as a strategic management tool to assess the current internal strengths and weaknesses of the Trial Clinical, and to figure out the opportunities and threats in the macro environment – technological, environmental, political, economic, social, demographic, etc in which Trial Clinical operates in.
According to Harvard Business Review, 75% of the managers use SWOT analysis for various purposes such as – evaluating current scenario, strategic planning, new venture feasibility, personal growth goals, new market entry, Go To market strategies, portfolio management and strategic trade-off assessment, organizational restructuring, etc.
SWOT Objectives / Importance of SWOT Analysis and SWOT Matrix
SWOT analysis of Solnyx Pharmaceuticals: The Atoxeril Clinical Trial can be done for the following purposes –
1. Strategic planning using facts provided in Solnyx Pharmaceuticals: The Atoxeril Clinical Trial case study
2. Improving business portfolio management of Trial Clinical
3. Assessing feasibility of the new initiative in Technology & Operations field.
4. Making a Technology & Operations topic specific business decision
5. Set goals for the organization
6. Organizational restructuring of Trial Clinical
Strengths Solnyx Pharmaceuticals: The Atoxeril Clinical Trial | Internal Strategic Factors
What are Strengths in SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The strengths of Trial Clinical in Solnyx Pharmaceuticals: The Atoxeril Clinical Trial Harvard Business Review case study are -
Organizational Resilience of Trial Clinical
– The covid-19 pandemic has put organizational resilience at the centre of everthing that Trial Clinical does. Organizational resilience comprises - Financial Resilience, Operational Resilience, Technological Resilience, Organizational Resilience, Business Model Resilience, and Reputation Resilience.
Highly skilled collaborators
– Trial Clinical has highly efficient outsourcing and offshoring strategy. It has resulted in greater operational flexibility and bringing down the costs in highly price sensitive segment. Secondly the value chain collaborators of the firm in Solnyx Pharmaceuticals: The Atoxeril Clinical Trial HBR case study have helped the firm to develop new products and bring them quickly to the marketplace.
Analytics focus
– Trial Clinical is putting a lot of focus on utilizing the power of analytics in business decision making. This has put it among the leading players in the industry. The technology infrastructure suggested by Gregory S. Zaric, James E. Hatch can also help it to harness the power of analytics for – marketing optimization, demand forecasting, customer relationship management, inventory management, information sharing across the value chain etc.
Sustainable margins compare to other players in Technology & Operations industry
– Solnyx Pharmaceuticals: The Atoxeril Clinical Trial firm has clearly differentiated products in the market place. This has enabled Trial Clinical to fetch slight price premium compare to the competitors in the Technology & Operations industry. The sustainable margins have also helped Trial Clinical to invest into research and development (R&D) and innovation.
Effective Research and Development (R&D)
– Trial Clinical has innovation driven culture where significant part of the revenues are spent on the research and development activities. This has resulted in, as mentioned in case study Solnyx Pharmaceuticals: The Atoxeril Clinical Trial - staying ahead in the industry in terms of – new product launches, superior customer experience, highly competitive pricing strategies, and great returns to the shareholders.
Training and development
– Trial Clinical has one of the best training and development program in the industry. The effectiveness of the training programs can be measured in Solnyx Pharmaceuticals: The Atoxeril Clinical Trial Harvard Business Review case study by analyzing – employees retention, in-house promotion, loyalty, new venture initiation, lack of conflict, and high level of both employees and customer engagement.
Digital Transformation in Technology & Operations segment
- digital transformation varies from industry to industry. For Trial Clinical digital transformation journey comprises differing goals based on market maturity, customer technology acceptance, and organizational culture. Trial Clinical has successfully integrated the four key components of digital transformation – digital integration in processes, digital integration in marketing and customer relationship management, digital integration into the value chain, and using technology to explore new products and market opportunities.
Operational resilience
– The operational resilience strategy in the Solnyx Pharmaceuticals: The Atoxeril Clinical Trial Harvard Business Review case study comprises – understanding the underlying the factors in the industry, building diversified operations across different geographies so that disruption in one part of the world doesn’t impact the overall performance of the firm, and integrating the various business operations and processes through its digital transformation drive.
Superior customer experience
– The customer experience strategy of Trial Clinical in the segment is based on four key concepts – personalization, simplification of complex needs, prompt response, and continuous engagement.
Ability to recruit top talent
– Trial Clinical is one of the leading recruiters in the industry. Managers in the Solnyx Pharmaceuticals: The Atoxeril Clinical Trial are in a position to attract the best talent available. The firm has a robust talent identification program that helps in identifying the brightest.
Learning organization
- Trial Clinical is a learning organization. It has inculcated three key characters of learning organization in its processes and operations – exploration, creativity, and expansiveness. The work place at Trial Clinical is open place that encourages instructiveness, ideation, open minded discussions, and creativity. Employees and leaders in Solnyx Pharmaceuticals: The Atoxeril Clinical Trial Harvard Business Review case study emphasize – knowledge, initiative, and innovation.
Strong track record of project management
– Trial Clinical is known for sticking to its project targets. This enables the firm to manage – time, project costs, and have sustainable margins on the projects.
Weaknesses Solnyx Pharmaceuticals: The Atoxeril Clinical Trial | Internal Strategic Factors
What are Weaknesses in SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The weaknesses of Solnyx Pharmaceuticals: The Atoxeril Clinical Trial are -
Need for greater diversity
– Trial Clinical has taken concrete steps on diversity, equity, and inclusion. But the efforts so far has resulted in limited success. It needs to expand the recruitment and selection process to hire more people from the minorities and underprivileged background.
Slow decision making process
– As mentioned earlier in the report, Trial Clinical has a very deliberative decision making approach. This approach has resulted in prudent decisions, but it has also resulted in missing opportunities in the industry over the last five years. Trial Clinical even though has strong showing on digital transformation primary two stages, it has struggled to capitalize the power of digital transformation in marketing efforts and new venture efforts.
Capital Spending Reduction
– Even during the low interest decade, Trial Clinical has not been able to do capital spending to the tune of the competition. This has resulted into fewer innovations and company facing stiff competition from both existing competitors and new entrants who are disrupting the industry using digital technology.
Workers concerns about automation
– As automation is fast increasing in the segment, Trial Clinical needs to come up with a strategy to reduce the workers concern regarding automation. Without a clear strategy, it could lead to disruption and uncertainty within the organization.
High dependence on existing supply chain
– The disruption in the global supply chains because of the Covid-19 pandemic and blockage of the Suez Canal illustrated the fragile nature of Trial Clinical supply chain. Even after few cautionary changes mentioned in the HBR case study - Solnyx Pharmaceuticals: The Atoxeril Clinical Trial, it is still heavily dependent upon the existing supply chain. The existing supply chain though brings in cost efficiencies but it has left Trial Clinical vulnerable to further global disruptions in South East Asia.
Products dominated business model
– Even though Trial Clinical has some of the most successful products in the industry, this business model has made each new product launch extremely critical for continuous financial growth of the organization. firm in the HBR case study - Solnyx Pharmaceuticals: The Atoxeril Clinical Trial should strive to include more intangible value offerings along with its core products and services.
Slow to strategic competitive environment developments
– As Solnyx Pharmaceuticals: The Atoxeril Clinical Trial HBR case study mentions - Trial Clinical takes time to assess the upcoming competitions. This has led to missing out on atleast 2-3 big opportunities in the industry in last five years.
No frontier risks strategy
– After analyzing the HBR case study Solnyx Pharmaceuticals: The Atoxeril Clinical Trial, it seems that company is thinking about the frontier risks that can impact Technology & Operations strategy. But it has very little resources allocation to manage the risks emerging from events such as natural disasters, climate change, melting of permafrost, tacking the rise of artificial intelligence, opportunities and threats emerging from commercialization of space etc.
Skills based hiring
– The stress on hiring functional specialists at Trial Clinical has created an environment where the organization is dominated by functional specialists rather than management generalist. This has resulted into product oriented approach rather than marketing oriented approach or consumers oriented approach.
High dependence on star products
– The top 2 products and services of the firm as mentioned in the Solnyx Pharmaceuticals: The Atoxeril Clinical Trial HBR case study still accounts for major business revenue. This dependence on star products in has resulted into insufficient focus on developing new products, even though Trial Clinical has relatively successful track record of launching new products.
Slow to harness new channels of communication
– Even though competitors are using new communication channels such as Instagram, Tiktok, and Snap, Trial Clinical is slow explore the new channels of communication. These new channels of communication mentioned in marketing section of case study Solnyx Pharmaceuticals: The Atoxeril Clinical Trial can help to provide better information regarding products and services. It can also build an online community to further reach out to potential customers.
Opportunities Solnyx Pharmaceuticals: The Atoxeril Clinical Trial | External Strategic Factors
What are Opportunities in the SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The opportunities highlighted in the Harvard Business Review case study Solnyx Pharmaceuticals: The Atoxeril Clinical Trial are -
Reforming the budgeting process
- By establishing new metrics that will be used to evaluate both existing and potential projects Trial Clinical can not only reduce the costs of the project but also help it in integrating the projects with other processes within the organization.
Using analytics as competitive advantage
– Trial Clinical has spent a significant amount of money and effort to integrate analytics and machine learning into its operations in the sector. This continuous investment in analytics has enabled, as illustrated in the Harvard case study Solnyx Pharmaceuticals: The Atoxeril Clinical Trial - to build a competitive advantage using analytics. The analytics driven competitive advantage can help Trial Clinical to build faster Go To Market strategies, better consumer insights, developing relevant product features, and building a highly efficient supply chain.
Leveraging digital technologies
– Trial Clinical can leverage digital technologies such as artificial intelligence and machine learning to automate the production process, customer analytics to get better insights into consumer behavior, realtime digital dashboards to get better sales tracking, logistics and transportation, product tracking, etc.
Remote work and new talent hiring opportunities
– The widespread usage of remote working technologies during Covid-19 has opened opportunities for Trial Clinical to expand its talent hiring zone. According to McKinsey Global Institute, 20% of the high end workforce in fields such as finance, information technology, can continously work from remote local post Covid-19. This presents a really great opportunity for Trial Clinical to hire the very best people irrespective of their geographical location.
Use of Bitcoin and other crypto currencies for transactions
– The popularity of Bitcoin and other crypto currencies as asset class and medium of transaction has opened new opportunities for Trial Clinical in the consumer business. Now Trial Clinical can target international markets with far fewer capital restrictions requirements than the existing system.
Loyalty marketing
– Trial Clinical has focused on building a highly responsive customer relationship management platform. This platform is built on in-house data and driven by analytics and artificial intelligence. The customer analytics can help the organization to fine tune its loyalty marketing efforts, increase the wallet share of the organization, reduce wastage on mainstream advertising spending, build better pricing strategies using personalization, etc.
Buying journey improvements
– Trial Clinical can improve the customer journey of consumers in the industry by using analytics and artificial intelligence. Solnyx Pharmaceuticals: The Atoxeril Clinical Trial suggest that firm can provide automated chats to help consumers solve their own problems, provide online suggestions to get maximum out of the products and services, and help consumers to build a community where they can interact with each other to develop new features and uses.
Better consumer reach
– The expansion of the 5G network will help Trial Clinical to increase its market reach. Trial Clinical will be able to reach out to new customers. Secondly 5G will also provide technology framework to build new tools and products that can help more immersive consumer experience and faster consumer journey.
Redefining models of collaboration and team work
– As explained in the weaknesses section, Trial Clinical is facing challenges because of the dominance of functional experts in the organization. Solnyx Pharmaceuticals: The Atoxeril Clinical Trial case study suggests that firm can utilize new technology to build more coordinated teams and streamline operations and communications using tools such as CAD, Zoom, etc.
Changes in consumer behavior post Covid-19
– Consumer behavior has changed in the Technology & Operations industry because of Covid-19 restrictions. Some of this behavior will stay once things get back to normal. Trial Clinical can take advantage of these changes in consumer behavior to build a far more efficient business model. For example consumer regular ordering of products can reduce both last mile delivery costs and market penetration costs. Trial Clinical can further use this consumer data to build better customer loyalty, provide better products and service collection, and improve the value proposition in inflationary times.
Learning at scale
– Online learning technologies has now opened space for Trial Clinical to conduct training and development for its employees across the world. This will result in not only reducing the cost of training but also help employees in different part of the world to integrate with the headquarter work culture, ethos, and standards.
Reconfiguring business model
– The expansion of digital payment system, the bringing down of international transactions costs using Bitcoin and other blockchain based currencies, etc can help Trial Clinical to reconfigure its entire business model. For example it can used blockchain based technologies to reduce piracy of its products in the big markets such as China. Secondly it can use the popularity of e-commerce in various developing markets to build a Direct to Customer business model rather than the current Channel Heavy distribution network.
Increase in government spending
– As the United States and other governments are increasing social spending and infrastructure spending to build economies post Covid-19, Trial Clinical can use these opportunities to build new business models that can help the communities that Trial Clinical operates in. Secondly it can use opportunities from government spending in Technology & Operations sector.
Threats Solnyx Pharmaceuticals: The Atoxeril Clinical Trial External Strategic Factors
What are Threats in the SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The threats mentioned in the HBR case study Solnyx Pharmaceuticals: The Atoxeril Clinical Trial are -
Capital market disruption
– During the Covid-19, Dow Jones has touched record high. The valuations of a number of companies are way beyond their existing business model potential. This can lead to capital market correction which can put a number of suppliers, collaborators, value chain partners in great financial difficulty. It will directly impact the business of Trial Clinical.
Aging population
– As the populations of most advanced economies are aging, it will lead to high social security costs, higher savings among population, and lower demand for goods and services in the economy. The household savings in US, France, UK, Germany, and Japan are growing faster than predicted because of uncertainty caused by pandemic.
Regulatory challenges
– Trial Clinical needs to prepare for regulatory challenges as consumer protection groups and other pressure groups are vigorously advocating for more regulations on big business - to reduce inequality, to create a level playing field, to product data privacy and consumer privacy, to reduce the influence of big money on democratic institutions, etc. This can lead to significant changes in the Technology & Operations industry regulations.
High level of anxiety and lack of motivation
– the Great Resignation in United States is the sign of broader dissatisfaction among the workforce in United States. Trial Clinical needs to understand the core reasons impacting the Technology & Operations industry. This will help it in building a better workplace.
Trade war between China and United States
– The trade war between two of the biggest economies can hugely impact the opportunities for Trial Clinical in the Technology & Operations industry. The Technology & Operations industry is already at various protected from local competition in China, with the rise of trade war the protection levels may go up. This presents a clear threat of current business model in Chinese market.
Technology acceleration in Forth Industrial Revolution
– Trial Clinical has witnessed rapid integration of technology during Covid-19 in the Technology & Operations industry. As one of the leading players in the industry, Trial Clinical needs to keep up with the evolution of technology in the Technology & Operations sector. According to Mckinsey study top managers believe that the adoption of technology in operations, communications is 20-25 times faster than what they planned in the beginning of 2019.
Increasing international competition and downward pressure on margins
– Apart from technology driven competitive advantage dilution, Trial Clinical can face downward pressure on margins from increasing competition from international players. The international players have stable revenue in their home market and can use those resources to penetrate prominent markets illustrated in HBR case study Solnyx Pharmaceuticals: The Atoxeril Clinical Trial .
Barriers of entry lowering
– As technology is more democratized, the barriers to entry in the industry are lowering. It can presents Trial Clinical with greater competitive threats in the near to medium future. Secondly it will also put downward pressure on pricing throughout the sector.
New competition
– After the dotcom bust of 2001, financial crisis of 2008-09, the business formation in US economy had declined. But in 2020 alone, there are more than 1.5 million new business applications in United States. This can lead to greater competition for Trial Clinical in the Technology & Operations sector and impact the bottomline of the organization.
Shortening product life cycle
– it is one of the major threat that Trial Clinical is facing in Technology & Operations sector. It can lead to higher research and development costs, higher marketing expenses, lower customer loyalty, etc.
Technology disruption because of hacks, piracy etc
– The colonial pipeline illustrated, how vulnerable modern organization are to international hackers, miscreants, and disruptors. The cyber security interruption, data leaks, etc can seriously jeopardize the future growth of the organization.
High dependence on third party suppliers
– Trial Clinical high dependence on third party suppliers can disrupt its processes and delivery mechanism. For example -the current troubles of car makers because of chip shortage is because the chip companies started producing chips for electronic companies rather than car manufacturers.
Stagnating economy with rate increase
– Trial Clinical can face lack of demand in the market place because of Fed actions to reduce inflation. This can lead to sluggish growth in the economy, lower demands, lower investments, higher borrowing costs, and consolidation in the field.
Weighted SWOT Analysis of Solnyx Pharmaceuticals: The Atoxeril Clinical Trial Template, Example
Not all factors mentioned under the Strengths, Weakness, Opportunities, and Threats quadrants in the SWOT Analysis are equal. Managers in the HBR case study Solnyx Pharmaceuticals: The Atoxeril Clinical Trial needs to zero down on the relative importance of each factor mentioned in the Strengths, Weakness, Opportunities, and Threats quadrants.
We can provide the relative importance to each factor by assigning relative weights. Weighted SWOT analysis process is a three stage process –
First stage for doing weighted SWOT analysis of the case study Solnyx Pharmaceuticals: The Atoxeril Clinical Trial is to rank the strengths and weaknesses of the organization. This will help you to assess the most important strengths and weaknesses of the firm and which one of the strengths and weaknesses mentioned in the initial lists are marginal and can be left out.
Second stage for conducting weighted SWOT analysis of the Harvard case study Solnyx Pharmaceuticals: The Atoxeril Clinical Trial is to give probabilities to the external strategic factors thus better understanding the opportunities and threats arising out of macro environment changes and developments.
Third stage of constructing weighted SWOT analysis of Solnyx Pharmaceuticals: The Atoxeril Clinical Trial is to provide strategic recommendations includes – joining likelihood of external strategic factors such as opportunities and threats to the internal strategic factors – strengths and weaknesses. You should start with external factors as they will provide the direction of the overall industry. Secondly by joining probabilities with internal strategic factors can help the company not only strategic fit but also the most probably strategic trade-off that Trial Clinical needs to make to build a sustainable competitive advantage.
